Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review (Q38037349)

27 August 2017

Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review (English)

1 reference

27 August 2017

0 references

1 reference

James Carroll

1

0 references

Melinda Protani

object named as

Melinda Protani

series ordinal

2

0 references

Euan Walpole

object named as

Euan Walpole

series ordinal

3

0 references

Jennifer Martin

object named as

Jennifer H Martin

series ordinal

4

0 references

language of work or name

English

0 references

publication date

24 August 2012

1 reference

Breast Cancer Research and Treatment

27 August 2017

1 reference

27 August 2017

136

1 reference

27 August 2017

2

1 reference

27 August 2017

323-330

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2213-3

27 August 2017

0 references

cites work

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Effect of obesity on the pharmacokinetics of drugs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Relationships between body composition parameters and fluorouracil pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Description of current practices of empiric chemotherapy dose adjustment in obese adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Effects of obesity on pharmacokinetics implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Dose-response effect of adjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2213-3

10.1007/S10549-012-2213-3

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

22918525

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22918525